Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET
Public ClinicalTrials.gov record NCT03993873. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 of Study of the Safety, Tolerability, Pharmacokinetics, and Efficacy of TPX-0022 in Adult Subjects With Locally Advanced or Metastatic NSCLC, Gastric Cancer, or Solid Tumors Harboring Genetic Alterations in MET
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A phase 1/2, first-in-human, open-label study of the safety, tolerability, PK, and efficacy of the novel MET/CSF1R/SRC inhibitor TPX-0022 in adult subjects with advanced or metastatic NSCLC, Gastric Cancer, or solid tumors harboring genetic alterations in MET. (SHIELD-I)
Study identification
- NCT ID
- NCT03993873
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 95 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 5, 2019 (Actual)
- Primary completion
- Jan 8, 2024 (Actual)
- Completion
- Mar 3, 2027 (Estimated)
- Last update posted
- Oct 1, 2025
2019 – 2027
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 2102 | La Jolla | California | 92093 | — |
| Local Institution - 2108 | Orange | California | 92868 | — |
| Local Institution - 2105 | Denver | Colorado | 80218 | — |
| Local Institution - 2111 | Chicago | Illinois | 60637 | — |
| Local Institution - 2107 | Boston | Massachusetts | 02114 | — |
| Local Institution - 2109 | Boston | Massachusetts | 02215 | — |
| Local Institution - 2106 | Ann Arbor | Michigan | 48109 | — |
| Local Institution - 2113 | Detroit | Michigan | 48202 | — |
| Local Institution - 2103 | St Louis | Missouri | 63110 | — |
| Local Institution - 2104 | Toledo | Ohio | 43614 | — |
| Local Institution - 2101 | Houston | Texas | 77030-4009 | — |
| Local Institution - 2112 | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03993873, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 1, 2025 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03993873 live on ClinicalTrials.gov.